STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Sionna Therapeutics announced Monday that its experimental cystic fibrosis pill SION-719 showed no benefit when added to Vertex Pharmaceuticals' Trikafta in a Phase 2 trial.
- Sionna will no longer advance SION-719 as an add-on therapy for CF patients, calling Monday's results 'a major blow.'
- The company hinted at potential layoffs, saying it will 'take actions to preserve capital while evaluating next steps.'
- Sionna was founded in 2019 — the same year Trikafta reached the market and transformed treatment for tens of thousands of CF patients while earning Vertex billions.
- The Phase 2 trial tested SION-719 as an add-on to Trikafta, which already dominates the CF treatment landscape, leaving no clear near-term oral challenger on the horizon.
Why it matters: For Sionna, a company founded in 2019 with the explicit goal of challenging CF treatment, the Phase 2 failure constitutes 'a major blow' per the company, which is now taking actions to preserve capital — including hinted layoffs — while it evaluates next steps.
Ask SkimNews
